From monoclonal antibodies (mAb) to recombinant proteins ... biologics offers a cost-effective solution. The market for ‘biosimilars’ is booming in China and across the world.

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...

Antidrug antibodies may interfere with the efficacy of these agents. Future therapies will hopefully include cheaper biosimilars, which have only been recently become available in some countries.

Biosimilars provide a cost-effective alternative to expensive branded biologics, increasing accessibility for patients while driving competition among manufacturers. Technological Advancements in ...

positioning Amneal to have a portfolio of six biosimilars across eight product presentations by 2027. Denosumab is a monoclonal antibody drug that inhibits bone reabsorption. It is indicated for ...

FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, launched ... Ustekinumab is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23 which play ...

CT-P13, intravenous infliximab, developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar therapy and has been the most established biosimilar treatment in the Canadian ...